



(51) International Patent Classification:

C08B 37/08 (2006.01) A61L 27/52 (2006.01)
C08L 5/08 (2006.01) C08J 3/075 (2006.01)
A61K 8/73 (2006.01) A61K 9/00 (2006.01)
A61K 31/728 (2006.01) C08J3/24 (2006.01)
A61K 47/36 (2006.01)

(21) International Application Number:

PCT/EP20 13/00 1782

(22) International Filing Date:

14 June 2013 (14.06.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/660,269 15 June 2012 (15.06.2012) US
12004962.2 4 July 2012 (04.07.2012) EP
13000961.6 26 February 2013 (26.02.2013) EP

(71) Applicant: **MERZ PHARMA GMBH & CO. KGAA**
[DE/DE]; Eckenheimer Landstrasse 100, 603 18 Frankfurt
am Main (DE).

(72) Inventors: **BARG, Heiko**; Siegfriedstr. 25, 69469 Wein-
heim (DE). **FRIEDRICH, Josef**; Im Warmet 13, 69231
Rauenberg (DE). **LIEBETRAU, Wolfgang**; Theodor-
Heuss-Str. 2, 6 1169 Friedberg (DE). **VOIGTS, Robert,**
G.; 8236 Burgandy Dr., Windlake, WI 53185 (US). **LIG-**
MAN, Tim, Stephen; 1305 Regent Drive, Mundelein, IL
60060 (US).

(74) Agent: **RICKER, Mathias**; Wallinger Ricker Schlotter
Tostmann, Zweibrueckenstrasse 5-7, 8033 1 Munchen
(DE).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD OF PREPARING A COMPOSITION BASED ON HYALURONIC ACID

(57) Abstract: The invention relates to a method of preparing a composition, the composition comprising a crosslinked first poly-
mer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer
are selected from a polysaccharide, comprising at least steps (i) to (iv): (i) crosslinking a mixture comprising the first polymer and
water; (ii) subsequent to the crosslinking in step (i), terminating the crosslinking; (iii) optionally blending the product obtained in
step (ii) with the second polymer; (iv) subjecting the product obtained in step (iii) to dialysis.



METHOD OF PREPARING A COMPOSITION BASED ON HYALURONIC ACID

FIELD OF THE INVENTION

[0001] The invention relates to a method of preparing a composition, such as a gel, based on a polysaccharide, such as hyaluronic acid, to the composition as such, to a kit comprising a syringe and the composition, and to the use of the composition as a dermatological filler.

BACKGROUND OF THE INVENTION

[0002] It is known to use gels such as hydrogels based on polysaccharides and water as dermatological fillers. Such gels are generally prepared by methods comprising the chemical cross-linking of the respective polysaccharides in an aqueous medium. Suitable polysaccharides are e.g. based on hyaluronic acid since it is present in identical or similar compositions in each living organism. E.g., hyaluronic acid is a major component of skin, where it is involved in tissue repair. Therefore, it gives a minimum of side effects and allows for safe application.

[0003] EP 1 818 344 relates to a process for preparing a crosslinked hyaluronic acid gel, comprising stirring and mixing a mixture containing 10 w/v % or more of hyaluronic acid, a crosslinking agent, and water under acidic or alkaline condition.

[0004] EP 2 054 039 (WO 2008/018796) relates to a viscoelastic hydrogel composition comprising first microparticles and second microparticles capable of interacting with each other through stereocomplex interactions, wherein said first microparticles comprise a crosslinked first hydrophilic polymer, said first microparticles comprising external grafts of first oligomers or co-oligomers comprising

a first chiral region, said first chiral region comprising first chiral monomers, and wherein said second microparticles comprise a crosslinked second hydrophilic polymer, said second microparticles comprising external grafts of second oligomers or co-oligomers comprising a second chiral region, said second chiral region comprising second chiral monomers, said second chiral monomers having chirality that is opposite to the chirality of said first chiral monomers, wherein said first chiral region and said second chiral region interact with each other non-covalently. The hydrophilic polymer may be hyaluronic acid.

[0005] EP 2 178 923 (WO 2009/018076) relates to a process for the preparation of crosslinked hyaluronic acid, said process comprising contacting hyaluronic acid with a polyethylene glycol based crosslinking agent.

[0006] WO 201 1/1 19468 relates to a hydrogel for soft tissue augmentation comprising a cross-linked biocompatible polymer having zero-length cross-linked moieties and optionally at least one other active ingredient incorporated into said cross-linked biocompatible polymer.

[0007] EP 2 152 329 (WO 2008/068297) relates to an implant that can be injected subcutaneously or intradermally in the form of a single-phase hydrogel comprising a gel composed of crosslinked hyaluronic acid and one of its physiologically acceptable salts.

[0008] EP 2 170 961 (WO 2009/021526) relates to a hyaluronic acid dispersion for use in aesthetics medicine and orthopedics, wherein the dispersed phase comprises particles made of crosslinked hyaluronic acid, and the continuous phase substantially comprises linear hyaluronic acid.

[0009] EP 1 699 500 (WO 2005/067994) relates to a hyaluronic acid composition comprising crosslinked, water-insoluble, hydrated hyaluronic acid gel particles. The composition may be used for augmenting tissue in a subject that is in need of tissue augmentation, to a method of stabilizing crosslinked HA including hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G' for the stabilized composition is at least about 110% of the value of G' for a non-stabilized composition, and to the stabilized HA composition.

[0010] WO 2010/015900 relates to soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof, wherein the hyaluronic acid-based compositions may include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The hyaluronic acid-based compositions including lidocaine have an enhanced stability, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

[0011] FR 2 919 999 relates to a cosmetical composition or pharmaceutical composition, which comprises a hyaluronic acid and a divalent cation. The composition may be used for treating wrinkles.

[0012] EP 2 254 584 (WO 2009/098127) relates to biocompatible injectable products capable of releasing zinc and/or at least one saccharide salt in the form of zinc, to compositions containing said products, and to the use thereof in particular for filling or increasing the volume of biological tissues or for replacing or supplementing a biological fluid.

[0013] EP 2 155 212 (WO 2008/139122) relates to the association of hyaluronic acid and at least one inhibitor of hyaluronic acid degradation, which is intended, in particular, for use in human dermatology and plastic surgery.

[0014] EP 0 839 159 B1 discloses a process for preparing a cross-linked biocompatible polysaccharide gel composition. The process comprises the cross-linking of a polysaccharide in the presence of polyfunctional cross-linking agents, wherein a viscoelastic gel is formed.

[0015] EP 1 711 552 B1 relates a method for producing a biocompatible crosslinked gel comprising steps of crosslinking a biocompatible polymer, diluting the crosslinked polymer with non-crosslinked polymer, and terminating the crosslinking reaction.

[0016] EP 0 466 300 B1 relates to a method of obtaining a biocompatible viscoelastic gel slurry, the method comprising the mixing of a biocompatible gel, which comprises crosslinked hyaluronic acid, with a second polymer, which may e.g. be hyaluronic acid, to form a two phase mixture, and to the gel as such.

OBJECTS OF THE INVENTION

[0017] One object of the invention is to provide a process for the preparation of a composition, such as a gel, based on a polysaccharide, which may be used as a dermatological filler, wherein the composition should have an excellent stability, i.e. does not change its properties, in particular its viscoelastic properties, after application, and which may be adjusted in a tailor-made manner to dermatological requirements. Furthermore, the gel should have excellent compatibility with skin tissue.

SUMMARY OF THE INVENTION

[0018] This object is achieved with a method of preparing a composition, such as a gel, the composition comprising a cross-linked first polymer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide; and with the composition prepared according to said method.

[0019] Specifically, according to a *first aspect*, the invention relates to a method of preparing a composition, such as a gel, the composition comprising a crosslinked first polymer, optionally a second polymer, the second polymer may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, the method comprising at least steps (i) to (iv):

- (i) crosslinking a mixture comprising the first polymer and water;
- (ii) subsequent to the crosslinking in step (i), terminating the crosslinking;
- (iii) optionally blending the product obtained in step (ii) with the second polymer;
- (iv) subjecting the product obtained in step (ii) or step (iii) to dialysis.

[0020] In one embodiment, the presence of the second polymer is mandatory. In this embodiment, the method requires the blending of the product obtained in step (ii) with the second polymer according to step (iii).

[0021] In one embodiment, the presence of the second polymer is not necessary. In this embodiment, the method does not require the blending of the product obtained in step (ii) with the second polymer according to step (iii).

[0022] In one embodiment, the first and the second polymer may be the same.

[0023] In one embodiment, the first and the second polymer may be different from one another.

[0024] In one embodiment, the first polymer is crosslinked and the second polymer is non-crosslinked.

[0025] In one embodiment, the first and the second polymer are selected from a hyaluronic acid and a salt thereof.

[0026] In one embodiment, the first and the second polymer are selected from a hyaluronic acid or a salt thereof.

[0027] In one embodiment, the salt of hyaluronic acid is a sodium salt.

[0028] In one embodiment, the first polymer employed in step (i) has a molecular weight M_w of from 1.5 MDa to less than 3.5 MDa, or from 2.0 MDa to less than 3.5 MDa, or from 2.5 MDa to less than 3.0 MDa.

[0029] In one embodiment, the second polymer employed in step (iii) has a molecular weight of at least 3.0 MDa, or at least 3.5 MDa.

[0030] In one embodiment, the weight of the second polymer based on the weight of the first polymer is less than 5 %, or less than 4 %, e.g. is in the range of from 0.01 to 5 %, or is in the range of from 0.1 to 4 %, or is in the range of from 0.1 to 2.5 %, or from 0.2 to 2.0 %, or from 0.5 to 1.5 %.

[0031] In one embodiment, the method comprises after step (iv) a further step (v):

(v) admixing an anesthetic or anti-arrhythmic, such as lidocaine, or lidocaine hydrochloride, or lidocaine hydrochloride monohydrate, or tetracaine, to the product obtained in step (iv).

[0032] In one embodiment, the method comprises after step (iv), or after step (v), a further step (vi):

(vi) filling the product obtained in step (iv) or step (v) into a syringe and sterilizing it.

[0033] In one embodiment, the mixture of step (i) further comprises an alkaline phosphate buffer.

[0034] In one embodiment, said second polymer is provided in step (iii) in the form of a mixture with a phosphate buffer.

[0035] In one embodiment, said anesthetic or anti-arrhythmic, such as lidocaine or tetracaine provided in step (v), is provided in the form of a mixture with a phosphate buffer.

[0036] In one embodiment, the reaction temperature in step (i) is from 0 to 40 °C, e.g. from 15 to 40 °C; or from 25 to 35 °C, or from 25 to 30 °C; or from 30 to 35 °C.

[0037] In one embodiment, the reaction temperature in step (ii) is from 0 to 30 °C, e.g. from 0 to 10 °C; or from 3 to 7 °C.

[0038] In one embodiment, the reaction temperature in step (iii) is from 0 to 30 °C, e.g. from 0 to 10 °C; or from 3 to 7 °C.

[0039] In one embodiment, the reaction temperature in step (iv) is from 0 to 30 °C, e.g. from 0 to 10 °C; or from 3 to 7 °C.

[0040] In one embodiment, in step (i), a diglycidyl ether is used as crosslinking agent.

[0041] In one embodiment, in step (i), 1,4-butanediol diglycidyl ether (BDDE) is used as crosslinking agent.

[0042] In one embodiment, step (ii) comprises step (ii.1):

(ii.1) subjecting the product obtained in step (i) to an acid.

[0043] In one embodiment, step (ii) comprises steps (ii.1) and (ii.2):

(11.1) subjecting the product obtained in step (i) to an acid;

(11.2) extruding the product obtained in step (ii.1); or

extruding the product obtained in step (ii.1) through a sieve; or

extruding the product obtained in step (ii.1) through a sieve having a mesh size in the range of from 500 to 600 μm .

[0044] In one embodiment, said dialysis step according to step (iv) further comprises steps (iv.1) to (iv.3):

(iv.1) extruding the product obtained in step (iii) through a first sieve and subsequently extruding the extruded product from the first sieve through a second sieve, wherein the mesh size of the second sieve is less than the mesh size of the first sieve; or

extruding the product obtained in step (iii) through a first sieve, and subsequently extruding the extruded product from the first sieve through a

second sieve, and subsequently extruding the extruded product from the second sieve through a third sieve, wherein the mesh size of the second sieve is less than the mesh size of the first sieve, and the mesh size of the third sieve is less than the mesh size of the second sieve;

- (iv.2) filling the product obtained in step (iv.1) into a dialysis membrane;
- (iv.3) subjecting the filled membrane obtained in step (iv.2) to a dialysis solution.

[0045] In one embodiment, said dialysis step according to step (iv) further comprises steps (iv.1) to (iv.3):

- (iv.1) extruding the product obtained in step (iii) through a first sieve having a mesh size in the range of from 325 to 425 μm ; and subsequently extruding the extruded product from the first sieve through a second sieve having a mesh size in the range of from 175 to 225 μm ; and subsequently extruding the extruded product from the second sieve through a third sieve having a mesh size in the range of from 110 to 170 μm ;
- (iv.2) filling the product obtained in step (iv.1) into a dialysis membrane having a molecular weight cut off in the range of from 12,000 to 14,000 Da;
- (iv.3) subjecting the filled membrane obtained in step (iv.2) to a dialysis solution.

[0046] Any embodiment of the above embodiments may be combined with at least one further embodiment selected from the above embodiments.

[0047] According to a **second aspect**, the invention relates to a composition, such as a gel, the composition comprising a crosslinked first polymer, optionally a second polymer, the second polymer may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, obtainable by the method according to the **first aspect**, or according to the method of

the **first aspect** and any embodiment or any combination of at least two embodiments defined therein.

[0048] According to a **third aspect**, the invention relates to a kit, the kit comprising a syringe and the composition according to the **second aspect**, or the composition prepared according to the method according to the **first aspect**.

[0049] According to a **fourth aspect**, the invention relates to the use of the composition according to the **second aspect**, or to the use of the composition prepared according to the **first aspect**, in a cosmetic application.

[0050] In one embodiment, the composition is used as a dermatological filler.

[0051] According to a **fifth aspect**, the invention relates to a composition such as a gel according to the **second aspect** for use as a medicament.

DETAILED DESCRIPTION OF THE INVENTION

[0052] According to the **first aspect**, the invention relates to a method of preparing a composition comprising a crosslinked first polymer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, the method comprising at least steps (i) to (iv):

- (i) crosslinking a mixture comprising the first polymer and water;
- (ii) subsequent to the crosslinking in step (i), terminating the crosslinking;
- (iii) optionally blending the product obtained in step (ii) with the second polymer;
- (iv) subjecting the product obtained in step (ii) or step (iii) to dialysis.

[0053] The term "*composition*" as used in this disclosure encompasses a product comprising the crosslinked first polymer, optionally the second polymer, which may be crosslinked or non-crosslinked, and water.

[0054] In one embodiment, the composition is a gel such as a hydrogel. The term "*gel*" as used herein encompasses a product, which has both viscous and elastic properties. Thus, the term encompasses a viscoelastic product. In popular science, a gel sometimes is characterized as a jelly-like material. The viscoelastic properties of a gel may be determined by determining the loss modulus and the storage modulus of the gel.

[0055] The ratio between the loss module G'' and the storage module G' may be expressed by the loss factor $\tan\delta = G'' / G'$. The higher the loss factor, the more the properties of the product approach Newtonian flow. The viscosity of the product may be expressed in terms of η^* . Suitable methods for determining $\tan\delta$ and η^* are known in the art.

[0056] The composition or the composition such as the gel according to the invention mandatorily requires the use of a polysaccharide as the first, and if a second polymer is used also the use of a polysaccharide as the second polymer, in the method of the invention.

[0057] The term "*polysaccharide*" as used herein encompasses a carbohydrate molecule consisting or comprising repeated monomer units joint together by glycosidic bonds. In general, the polysaccharide contains more than 10 monosaccharide units. Examples of a polysaccharide are polysaccharides such as starch, glycogens, cellulose, chitin, or hyaluronic acid, or mixtures thereof.

[0058] In a preferred embodiment, the polysaccharide is a hyaluronic acid. The hyaluronic acid may be provided in the form of a salt thereof such as the sodium salt. It is also possible to provide a mixture of the acid and a salt thereof such as the sodium salt.

[0059] Thus, the term "*hyaluronic acid*" as used herein is synonymously used to terms such as "*hyaluronan*" or "*hyaluronate*". In the following, hyaluronic acid may be abbreviated with the term "*HA*".

[0060] HA is a non-crosslinked polymer of disaccharides. It can have up to 25.000 disaccharide units in length. The molecular weight of HA may range from 5,000 to 20,000,000 Da.

[0061] HA has a well recognized meaning in the art. It is commercially available in grades having different molecular weights (Mw) and / or different molecular weight distributions. It is available in non-crosslinked form as is used as starting material in step (i) of the method according to the invention.

Step (i)

[0062] Step (i) requires the crosslinking of a mixture comprising the first polymer and water.

[0063] The term "*crosslinking*" as used herein encompasses the linking of at least two different polymer chains of the polysaccharide by means of a chemical bond or chemical bonds. As a consequence, molecular weight of the first polymer is increased, and thus viscosity and / or elasticity.

[0064] In one embodiment, crosslinking is performed via a crosslinker.

[0065] Suitable crosslinker for crosslinking polysaccharides such as hyaluronic acids are known in the art.

[0066] In one embodiment, a crosslinker based on an epoxide-structure may be used in the method according to the invention.

[0067] In one embodiment, a diglycidylether is used for the crosslinking.

[0068] In one embodiment, 1,4-butanediol diglycidylether (BDDE) is used for the crosslinking. This compound is commercially available.

[0069] In one embodiment, the crosslinker is used in a quantity of from 5 to 15 % (volume crosslinker / weight of hyaluronic acid), such as 6 to 14 % (v/w), or 7 to 12 % (v/w).

[0070] Advantageously, the temperature in the crosslinking reaction according to step (i) is controlled.

[0071] In one embodiment, crosslinking according to step (i) is effected in a temperature range of from 0 to 40 °C.

[0072] In another embodiment, the temperature in step (i) is controlled such that it proceeds in a temperature range of from 15 to 40 °C

[0073] In one embodiment, the temperature in step (i) is from 25 to 35 °C.

[0074] In one embodiment, the temperature in step (i) is controlled such that the crosslinking proceeds in a temperature range of from 25 to 30 °C.

[0075] In another embodiment, the temperature in step (i) is controlled such that the crosslinking proceeds in a temperature range of from 30 to 35 °C, or from above 30 °C to 35 °C.

[0076] Such temperatures or temperature ranges may ensure a very homogenous crosslinking avoiding inhomogeneous particles as far as possible. Furthermore, in one embodiment, the control of the temperature allows the tailor-made adjustment of the viscoelastic properties of the composition according to the invention.

[0077] In one embodiment, if the crosslinking according to step (i) is performed at a higher temperature, e.g. in a temperature range of from above 30 to 35 °C, the viscoelastic properties of the resulting composition such as a gel is more intense compared to composition, in which the crosslinking has been performed at a lower temperature, e.g. at a temperature of from 25 °C to 30 °C. Such differences may be characterized by determining the storage modulus and the loss modulus of the composition according to methods known in the art. Accordingly, in one embodiment, the appropriate selection of the reaction temperature in step (i) allows for the preparation of compositions such as gels having different viscoelastic properties.

[0078] The term "*mixture*" as used herein encompasses a combination of two or more substances, which are mixed but not chemically bound to one another. Thus, the term "*mixture*" refers to a physical combination of the first polymer, which is a polysaccharide, and water. The mixture may be provided in the form of a solution, or a suspension, or a colloid.

[0079] The first polymer, i.e. the first polysaccharide, i.e. HA, in general has a molecular weight Mw in the range of from 1.0 to 4.0 MDa, or from 1.5 MDa to less

than 3.5 MDa, or from 2.0 MDa to less than 3.5 MDa. These ranges of molecular weight Mw relate to ranges before crosslinking, respectively.

[0080] In one embodiment, the first polysaccharide has a molecular weight Mw of from 2.5 MDa to less than 3.0 MDa, again before crosslinking.

[0081] Water may be provided in the form of pipe water, distilled water, or deionised water.

[0082] In one embodiment, the mixture used in step (i) additionally comprises a buffer solution.

[0083] In one embodiment, the buffer solution is a phosphate buffer solution.

[0084] In one embodiment, said phosphate buffer solution is made from sodium chloride, dibasic anhydrous sodium phosphate, monobasic sodium phosphate dihydrate and water.

[0085] In one embodiment, the buffer is an alkaline buffer.

[0086] In one embodiment, the p_H of the buffer is from 6.8 to 7.6, or from 7.0 to 7.4, or from 7.1 to 7.3.

[0087] In one embodiment, the p_H of the final composition prepared according to the method of the invention is adjusted to a range of from 6.5 to 7.5 such as 6.7 to 7.2, or 6.8 to 7.1 or 6.8 to 6.9. Such p_H may support the compatibility of the composition with skin tissue. For the adjustment of said p_H , in one embodiment, said buffer is used.

[0088] In one embodiment, step (i) may be effected by mixing the first polymer, water, the crosslinker, and optionally buffer solution, and stirring the mixture for a pre-determined time, wherein the temperature is controlled to not exceed the pre-determined setpoint.

Step (ii)

[0089] Step (ii) requires the termination of the crosslinking effected in step (i).

[0090] The termination of the crosslinking reaction according to step (ii) is mandatorily necessary since otherwise composition or gels may be obtained having a viscosity or a viscosity and elasticity being too high to allow for the appropriate use as dermatological filler, respectively the viscosity or the viscoelastic properties of the composition or gel are not constant as long as the gel contains compounds that may effect crosslinking such as the crosslinker used in step (i).

[0091] Basically, each compound capable of reacting with the crosslinker and thus deactivating it may be used for terminating the crosslinking reaction.

[0092] Since, in one embodiment, crosslinkers of the epoxide type are used in step (i), termination of the crosslinking may be effected by means of the addition of compounds, which cleave the epoxide moiety such that no further crosslinking with suitable groups in the polysaccharide can occur.

[0093] In one embodiment, cleavage of the epoxide and thus termination of the crosslinking in step (i) may be effected by an acid. Organic acids as well as inorganic acids may be used for terminating of crosslinking.

[0094] In one embodiment, an inorganic acid such as hydrochloric acid is used.

[0095] The compound used for termination of the crosslinking reaction may be applied in a buffer solution, e.g. in the buffer solution as used in step (i).

[0096] Such solution may be termed as "*quench solution*". Accordingly, termination according to step (ii) may be effected by quenching the crosslinked mixture obtained according to step (i).

[0097] In one embodiment, the termination of crosslinking according to step (ii) is effected in a temperature range of from 0 °C to 30 °C.

[0098] In another embodiment, the temperature in step (ii) is controlled such that it does not exceed a temperature of 20 °C, or 15 °C.

[0099] In one embodiment, the temperature in step (ii) is from 0 to 10 °C, or from 3 to 7 °C, e.g. 5 °C.

[00100] The termination according to step (ii) may be effected by adding the compound used for termination to the mixture according to step (i), and e.g. stirring it for a predetermined time.

[00101] The termination of the crosslinking reaction is crucial for the method according to the invention, since the thus obtained composition or gel has an excellent stability, i.e. it does not change its properties, in particular its viscosity or its viscoelastic properties, after application, e.g. after use as dermatological filler in the skin tissue.

[00102] In one embodiment, termination may further be supported by extruding in step (ii) the crosslinked product obtained in step (i), e.g. extruding the product

through a sieve. Without being bound by theory, it is believed that the high shear forces applied during extrusion provide for a thoroughly mixing of the crosslinker and the compound used for the termination of the crosslinking reaction in the composition or gel. As a consequence, the crosslinker is completely or nearly completely inactivated, thus preventing further crosslinking and thus further undesired increase of molecular weight and viscosity and/or elasticity.

[00103] The term "*extruding through a sieve*" encompasses terms such as "*passed through a sieve*", or "*pressed through a sieve*" or "*directed through a sieve*" or "*filtered*".

[00104] Thus, in one embodiment, step (ii) comprises step (ii.1):

(ii.1) extruding the crosslinked product obtained in step (i).

[00105] In another embodiment, step (ii) comprises steps (ii.1) and (ii.2):

(11.1) subjecting the product obtained in step (i) to an acid;

(11.2) extruding the product obtained in step (ii.1); or extruding the product obtained in step (ii.1) through a sieve.

[00106] In another embodiment, step (ii) comprises steps (ii.1) and (ii.2):

(11.1) subjecting the product obtained in step (i) to an acid;

(11.2) extruding the product obtained in step (ii.1); or
extruding the product obtained in step (ii.1) through a sieve; or
extruding the product obtained in step (ii.1) through a sieve having a mesh size in the range of from 500 to 600 μm .

[00107] In one embodiment, the mesh size of the sieve used in step (ii.2) is approximately 560 μm , such as 558.8 μm (0.022").

Step (iii)

[00108] Optional Step (iii) requires the blending of the product obtained in step (ii) with the second polymer.

[00109] In one embodiment, the presence of the second polymer is not necessary, and thus step (iii) is omitted in the reaction sequence of steps (i) to (iv).

[00110] In another embodiment, the presence of the second polymer is necessary, and thus step (iii) is necessarily performed in the reaction sequence of steps (i) to (iv).

[00111] The term "*blending*" as used herein encompasses the mixing of the crosslinked polymer obtained in step (ii) with the second polymer used in step (iii), wherein the obtained blend comprising the crosslinked first polymer and the second polymer, which may also be crosslinked, however, may also be provided in non-crosslinked form, has different physical properties with respect to the first and to the second polymer.

[00112] The second polymer is a polysaccharide, too. This polymer may be the same polymer as the first polymer, or may be different therefrom.

[00113] Thus, in one embodiment, the second polymer is the same HA as the first polymer used in step (i), or is a HA that is different from the HA used in step (i).

[001 14] In one embodiment, the first polymer has the same molecular weight as the second polymer. In another embodiment, the molecular weights are different from one another. The term "*molecular weight*" of said second polymer refers to the respective molecular weight of said polymer before blending and optionally crosslinking said second polymer.

[001 15] In one embodiment, the second polymer has a molecular weight of at least 3.0 MDa, or of at least 3.5 MDa, or of at least 4.0 MDa.

[001 16] In one embodiment, the second polymer has a molecular weight of at least 3.0 MDa, wherein the upper limit is 20 MDa, or 10 MDa, or 8 MDa, or 6 MDa, or 4 MDa, respectively.

[001 17] In one embodiment, the second polymer has a molecular weight of at least 3.5 MDa, wherein the upper limit is 20 MDa, or 10 MDa, or 8 MDa, or 6 MDa, or 4 MDa, respectively.

[001 18] In one embodiment, the second polymer has a molecular weight of at least 4.0 MDa, wherein the upper limit is 20 MDa, or 10 MDa, or 8 MDa, or 6 MDa, or 4 MDa, respectively.

[001 19] In one embodiment, the second polymer is provided in a buffer such as the buffer, which may be used in step (i) or in step (ii).

[00120] In one embodiment, the blending according to step (iii) is effected in a temperature range of from 0 °C to 40 °C, or from 0 °C to 30 °C.

[00121] In another embodiment, the temperature in step (iii) is controlled such that it does not exceed a temperature of 20 °C , or 15 °C.

[00122] In one embodiment, the temperature in step (iii) is from 0 to 10 °C, or from 3 to 7 °C; e.g. 5 °C.

[00123] In one embodiment, blending according to step (iii) is performed by stirring the crosslinked product, wherein the crosslinking has been terminated according to step (ii), with the second polymer.

[00124] In one embodiment, the weight of the second polymer based on the weight of the first polymer is less than 5 %, or less than 4 %, e.g. is in the range of from 0.01 to 5 %, or is in the range of from 0.1 to 4 %, or is in the range of from 0.1 to 2.5 %, or from 0.2 to 2.0 %, or from 0.5 to 1.5 %.

[00125] In one embodiment, step (iii) allows the tailor-made adjustment of properties with respect to viscosity and elasticity, or viscosity or elasticity of the target composition or gel, which are essential for the use as dermatological filler. Such properties may be achieved by selecting a suitable temperature range such in step (i) and / or weight ratio between the first and the second polymer in step (iii) and / or quantity of crosslinker used in step (i) and optionally used for the second polymer, provided that second polymer is employed in step (iii) and is employed in crosslinked form.

[00126] Furthermore, the use of a second polymer in step (iii) may improve the flowability of the composition through a sieve, if a sieving step is performed. Then, in general, lower extrusion forces are necessary to extrude the composition through said sieve or sieves as compared to a composition not containing said second

polymer. Moreover, the use of a second polymer in a non-crosslinked form may advantageously improve the flowability of the composition according to the invention through the needle of a syringe that is used to apply the composition in a cosmetic application. In turn, less force may be used to extrude the composition through said needle.

Step (iv)

[00127] Step (iv) requires the subjecting of the product obtained in step (ii) or (iii) to dialysis.

[00128] In one embodiment, this step serves for the removal of extraneous compounds or particles from the gel obtained in step (iii). Extraneous compounds or particles might negatively affect the physical properties of the composition such as a gel and / or might adversely affect the compatibility of the composition or gel with skin tissue. Thus, in one embodiment, step (iv) serves for the lowering or for the avoidance of possible inflammatory reactions when the composition according to the invention is injected into skin tissue.

[00129] In another embodiment, this step serves for adjusting the swelling of the gel obtained in step (ii) or step (iii).

[00130] The term "*swelling*" or "*swellability*" as used herein encompasses the water take-up of the gel.

[00131] In one embodiment, the swelling of the gel obtained in step (iii) when subjected to step (iv), i.e. the water-take up during dialysis, is from 5 to 25 % based on the total weight of the gel such as from 6 to 23 %, or from 7 to 22 %, or from 9 to 21 %.

[00132] In another embodiment, the swelling or swellability is from 7 to 18 %, or from 8 to 15 %.

[00133] In one embodiment, such swelling or swellability creates a swelling pressure that enables the HA matrix to withstand compressive forces, e.g. when injected into skin tissue and said skin tissue is exposed to compressive force.

[00134] In one embodiment, step (iv) serves for the removal of extraneous compounds or particles from the gel obtained in step (ii) or step (iii) and for adjusting the swelling of the gel obtained in step (ii) or step (iii).

[00135] Thus, step (iv) serves, among others, for the provision of a further improved HA composition as compared to products known in the art.

[00136] Thus, besides step (ii) (termination of the crosslinking), step (iv) (dialysis) is a further crucial reaction step in the sequence of steps required for the preparation of the composition such as a gel according to the invention. In particular the combination of step (ii) and step (iv) in the reaction sequence according to the invention allows the provision of a composition such as a gel having the properties, which should be achieved according to the posed problem.

[00137] In one embodiment, dialysis is performed using a dialysis membrane having a predetermined molecular weight cut off. Such dialysis membranes are commercially available

[00138] The term "*molecular weight cut off (MWCO)*" as used herein refers to the lowest molecular weight solute (in Daltons) in which a defined percentage of the solute is retained by the membrane used for dialysis, or refers to the molecular

weight at which a defined percentage of the analytes are prohibited from membrane diffusion.

[00139] Commercially available dialysis membranes typically have MWCOs that range from 1,000 to 100,000 Da.

[00140] In one embodiment, the used dialysis membrane has a MWCO in the range of from 12,000 to 14,000 Da.

[00141] In one embodiment, dialysis is performed using a dialysis solution comprising a buffer.

[00142] In one embodiment, the buffer is the buffer used in step (i), or used in step (ii), or used in step (iii).

[00143] In one embodiment, the dialysis according to step (iv) is effected in a temperature range of from 0 °C to 30 °C.

[00144] In another embodiment, the temperature in step (iv) is controlled such that it does not exceed a temperature of 20 °C, or 15 °C.

[00145] In one embodiment, the temperature in step (iv) is from 0 to 10 °C, or from 3 to 7 °C, e.g. 5 °C.

[00146] In one embodiment, the method according to the invention is performed such that the temperature in step (i) is from 25 to 35 °C, and the temperature in steps (ii) to (iv) is from 0 to 10 °C, respectively; or the method according to the invention is

performed such that the temperature in step (i) is from 25 to 35 °C, and the temperature in steps (ii) to (iv) is from 3 to 7 °C, e.g. 5 °C, respectively.

[00147] In one embodiment, prior to subjecting the product obtained in step (iii) to dialysis, the product may be subjected to a sieving step, or several sieving steps, in order to further homogenize the product, respectively to remove inhomogeneous particles or any further particles, which might negatively affect the use as dermatological filler.

[00148] In one embodiment, said dialysis step (iv) comprises steps (iv.1) to (iv.3):

- (iv.1) extruding the product obtained in step (ii) or step (iii) through a first sieve and subsequently extruding the extruded product from the first sieve through a second sieve, wherein the mesh size of the second sieve is less than the mesh size of the first sieve; or
extruding the product obtained in step (ii) or step (iii) through a first sieve, and subsequently extruding the extruded product from the first sieve through a second sieve, and subsequently extruding the extruded product from the second sieve through a third sieve, wherein the mesh size of the second sieve is less than the mesh size of the first sieve, and the mesh size of the third sieve is less than the mesh size of the second sieve;
- (iv.2) filling the product obtained in step (iv.1) into a dialysis membrane;
- (iv.3) subjecting the filled membrane obtained in step (iv.2) to a dialysis solution.

[00149] Such use of sieves prior to dialysis may further support the efficacy of dialysis step. The appropriate selection of the mesh size of the sieves further supports the removal of extraneous compounds and particles such as gelled particles, which negatively affect the desired homogeneity of the product. Thus, in

one embodiment, a sieving step or several sieving steps used in the method according to the invention allow for the preparation of a particularly homogeneous composition, i.e. a particularly homogeneous gel comprising the first polymer, optionally the second polymer, and water. Homogeneity is a desired property of the composition, which is obtained according to the method of the invention, and supports and improves the intended application such as the application of the composition in a cosmetic or medical use.

[00150] In one embodiment, said dialysis step (iv) comprises steps (iv.1) to (iv.3):

- (iv.1) extruding the product obtained in step (ii) or step (iii) through a first sieve having a mesh size in the range of from 325 to 425 μm ; and subsequently extruding the extruded product from the first sieve through a second sieve having a mesh size in the range of from 175 to 225 μm ; and subsequently extruding the extruded product from the second sieve through a third sieve having a mesh size in the range of from 110 to 170 μm ;
- (iv.2) filling the product obtained in step (iv.1) into a dialysis membrane having a molecular weight cut off in the range of from 12,000 to 14,000 Da;
- (iv.3) subjecting the filled membrane obtained in step (iv.2) to a dialysis solution.

[00151] In one embodiment, the gel obtained in step (ii) or step (iii) is extruded through a first sieve or screen having a mesh size of approximately 380 μm , such as 381 μm (0.015"), then through a second sieve or screen having a mesh size of approximately 200 μm , such as 203.2 μm (0.008"), then through a third sieve or screen having a mesh size of approximately 140 μm , such as 139.7 μm (0.0055"), into the dialysis membranes. The filled dialysis membrane or filled membranes are then placed into a container containing a suitable dialysis solution, such as the buffer solution used according to the first aspect of the invention with respect to step (i).

[00152] In one embodiment, if a blending step (iii) is performed after step (ii) and prior to dialysis step (iv), step (iii) facilitates the sieving steps, which are performed after step (iv) according to step (iv.1) .

[00153] In one embodiment, dialysis is performed by stirring the content of the container. In one embodiment, the dialysis solution may be exchanged once or at least twice by a fresh dialysis solution. In one embodiment, the interval of exchange ranges from 8 to 18 hours , or from 10 to 14 hours, such as 12 ± 2 hours. In one embodiment, dialysis according to step (iv) is allowed to proceed for 30 to 45 hours, or from 35 to 39 hours, such as 37 ± 2 hours.

[00154] In one embodiment, $\tan\delta$ of the composition obtained in step (iv) ranges from 0.1 to 0.9 measured at a frequency of 0.7 Hz and 30 °C such as from 0.1 to 0.5, or from 0.2 to 0.4.

[00155] In another embodiment, $\tan\delta$ of the composition obtained in step (iv) ranges from 0.1 to 3.5 measured at a frequency of 0.7 Hz and 30 °C.

[00156] In one embodiment, η^* is in the range of from 2,000 mPa*s to 200,000 mPa*s at a frequency of 0.7 Hz and 30 °C, wherein $\tan\delta$ ranges from 0.1 to 0.9, such as from 0.1 to 0.5, or from 0.2 to 0.4.

[00157] In one embodiment, $\tan\delta$ of the composition obtained in step (iv) ranges from 0.10 to 3.5 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, corresponding viscosity η^* is in the range of from 2,500 mPa*s to 145,000 mPa*s, or from 4,000 to 145,000 mPa*s.

[00158] In one embodiment, $\tan\delta$ of the composition obtained in step (iv) ranges from 0.10 to 3.5 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, $\tan\delta$ of the composition obtained in step (iv) ranges from 0.10 to 0.25 measured at a frequency of 0.7 Hz and 30 °C.

Step (v)

[00159] Although the composition according to the invention allows for an use, which avoids adverse skin reaction as far as possible, in one embodiment, a local anesthetic and / or anti-arrhythmic drug may be added to the composition or gel according to the invention obtained in step (iv), if necessary or desired. Such drug may relieve itching, burning and pain, which might arise from skin inflammation when the composition or gel according to the invention is injected into skin tissue.

[00160] Suitable drugs are known in the art.

[00161] In one embodiment, lidocaine is used as a local anesthetic and / or anti-arrhythmic drug. This drug is known for e.g. injection as a dental anesthetic or as a local anesthetic for minor surgery.

[00162] In one embodiment, lidocaine is used in the form of a salt such as the hydrochloride and / or in the form of a hydrate such as the monohydrate.

[00163] Accordingly, the term "*lidocaine*" as used herein, encompasses the salts and hydrates thereof.

[00164] In one embodiment, lidocaine is used in an amount of from 0 to 1 % by weight based on the weight of the composition or gel, or from 0 to 0.5 wt.-%.

[00165] In one embodiment, the weight is from 0.3 % to 0.35 %.

[00166] In one embodiment, the weight is 0.3 % or is 0.35 %.

[00167] In another embodiment, tetracaine is used. The term "*tetracaine*" as used herein, encompasses the salts and hydrates thereof. Tetracaine may be used in the same quantities as lidocaine.

[00168] In another embodiment, a mixture of lidocaine and tetracaine is used,

[00169] Accordingly, in one embodiment, the method according to the invention further comprises step (v) after step (iv):

(v) admixing an anesthetic or anti-arrhythmic or an anesthetic and anti-arrhythmic to the product obtained in step (iv).

[00170] In one embodiment, the method according to the invention further comprises step (v) after step (iv):

(v) admixing lidocaine, or lidocaine hydrochloride, or lidocaine hydrochloride monohydrate to the product obtained in step (iv); or admixing tetracaine to the product obtained in step (iv); or admixing lidocaine and tetracaine to the product obtained in step (iv).

[00171] In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.1 to 0.9 measured at a frequency of 0.7 Hz and 30 °C such as from 0.1 to 0.5, or from 0.2 to 0.4.

[00172] In another embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.1 to 3.5 or from 0.15 to 3.4 measured at a frequency of 0.7 Hz and 30 °C.

[00173] In one embodiment, η^* is in the range of from 2,000 mPa*s to 200,000 mPa*s at a frequency of 0.7 Hz and 30 °C, wherein $\tan\delta$ ranges from 0.1 to 0.9, such as from 0.1 to 0.5, or from 0.2 to 0.4.

[00174] In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.10 to 3.5 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, corresponding viscosity η^* is in the range of from 2,500 mPa*s to 145,000 mPa*s, or from 4,000 to 145,000 mPa*s.

[00175] In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.10 to 3.5 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.10 to 0.25 measured at a frequency of 0.7 Hz and 30 °C.

[00176] In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.1 to 3.5 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, corresponding viscosity η^* is in the range of from 2,000 mPa*s to 150,000 mPa*s. In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.15 to 3.5 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, corresponding viscosity η^* is in the range of from 2,500 mPa*s to 145,000 mPa*s, or from 4,000 to 145,000 mPa*s.

[00177] In one embodiment, $\tan\delta$ of the composition obtained in step (v) ranges from 0.15 to 0.25 measured at a frequency of 0.7 Hz and 30 °C. In one embodiment, the corresponding viscosity η^* is in the range of from 15,000 mPa*s to 28,000 mPa*s.

Step (vi)

[00178] Finally, in one embodiment, the product obtained in step (iv) or step (v) may be filled into a syringe. This is since the product obtained in the method according to the invention is intended to be injected for application

[00179] In one embodiment, the product obtained in step (iv) or step (v) is filled into a syringe, and is sterilized.

[00180] Accordingly, in one embodiment, the method according to the invention further comprises step (vi) after step (iv) or step (v):

(vi) filling the product obtained in step (iv) or step (v) into a syringe and sterilizing it.

[00181] In one embodiment, the product obtained in step (iv) or step (v) is extruded into the syringe, whereby the filling is effected.

[00182] Sterilization may be effected by methods known in the art. The term "*sterilization*" as used herein encompasses any process that eliminates or removes or kills all forms of microbial life, including transmissible agents (such as fungi, bacteria, viruses, spore forms, etc.) present on the surface of the syringe and / or in the composition or gel prepared according to the method of the invention. Sterilization may be achieved by the methods known in the art such as applying heat, chemicals, irradiation, high pressure or filtration, or a proper combination thereof.

[00183] In one embodiment, sterilization is effected prior to the filling according to step (vi), i.e. the composition or gel obtained in step (iv), or obtained in step (v), and the syringe are sterilized independently from one another.

[00184] In another embodiment, sterilization is effected during the filling according to step (vi).

[00185] In another embodiment, sterilization is effected after the filling according to step (vi).

[00186] In one embodiment, the overall content of HA in the final composition, such as the gel, is in the range of from 1 to 5 % by weight based on the total weight of the composition. In another embodiment, the overall content is in the range of from 1.5 to 4 % by weight, or from 2 to 2.5 % by weight.

[00187] In one embodiment, the product obtained according to step (iv), or obtained according to step (v), or obtained according to step (vi), is an isotonic, sterile, viscoelastic composition such as a gel. This composition or gel is injectable and may act as an implant to increase the volume of skin tissue, i.e. to augment it.

[00188] In one embodiment, the product obtained according to step (iv), or obtained according to step (v), or obtained according to step (vi), is an isotonic, sterile, viscoelastic injectable gel or implant to increase the volume of e.g. face skin tissue, or to correct moderate or deep wrinkles.

[00189] In one embodiment, the skin tissue comprises or is the tissue of the lips.

[00190] In another embodiments, the skin tissue comprises or is the skin tissue of moderate to severe facial wrinkles or folds, such as nasolabial folds.

[00191] In one embodiment, the composition prepared according to the **first aspect** of the invention, provides for a safe and effective, biocompatible, non-immunogenic

composition, which is easy to distribute and store, and which should not require allergy testing. Additionally, the composition has an acceptable persistency when applied to skin tissue. In one embodiment, the composition prepared according to the method of the invention is stable for a considerable time period, when applied to skin tissue.

[00192] Accordingly, in one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the composition obtained in step (iii) is dialyzed in step (iv) such to have a p_H in the range of from 6.5 to 7.5 such as 6.7 to 7.2, or from 6.8 to 7.1 or from 6.8 to 6.9.

[00193] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the gel obtained in step (iii) is dialyzed in step (iv) such to have a swellability in the range of from 5 to 25 % based on the total weight of the gel, such as from 6 to 23 % or from 7 to 22 % or from 9 to 21 %.

[00194] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein $\tan\delta$ of the composition obtained in step (iv) or step (v) ranges from 0.1 to 0.9 measured at a frequency of 0.7 Hz and 30 °C and/or viscosity η^* is in the range of from 2,000 mPa*s to 200,000 mPa*s; or ranges from 0.1 to 3.5 measured at a frequency of 0.7 Hz and 30 °C and/or viscosity η^* is in the range of from 2,000 mPa*s to 150,000 mPa*s; or $\tan\delta$ of the composition obtained in step (iv) or step (v)

ranges from 0.15 to 3.5 measured at a frequency of 0.7 Hz and 30 °C and/or viscosity η^* is in the range of from 2,100 mPa*s to 145,000 mPa*s, or from 2,500 to 145,000 mPa*s, or from 4,000 to 145,000 mPa*s, measured at a frequency of 0.7 Hz and 30 °C; or $\tan\delta$ of the composition obtained in step (iv) or step (v) ranges from 0.10 to 0.25 measured at a frequency of 0.7 Hz and 30 °C and/or viscosity η^* is in the range of from 15,000 mPa*s to 28,000 mPa*s measured at a frequency of 0.7 Hz and 30 °C; or $\tan\delta$ of the composition obtained in step (iv) or step (v) ranges from 0.10 to 0.25 measured at a frequency of 0.7 Hz and 30 °C and/or viscosity η^* is in the range of from 22,000 mPa*s to 28,000 mPa*s measured at a frequency of 0.7 Hz and 30 °C.

[00195] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the composition, when injected into skin tissue, is stable for at least three months, such as for at least 4 months, or five months, or six months.

[00196] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein said anesthetic and/or anti-arrhythmic, such as lidocaine or tetracaine, or lidocaine and tetracaine of step (v), is released when injected into skin tissue; and wherein the composition is sterile.

[00197] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the overall content of HA in the final composition, such as a gel, is in

the range of from 1 to 5 % by weight based on the total weight of the composition, such as from 1.5 to 4 % by weight, or from 2 to 2.5 % by weight.

[00198] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the composition does not irritate skin tissue when injected into said skin tissue.

[00199] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the composition is used as an injectable tissue filler while the composition is in the form of a gel.

[00200] In one embodiment, the invention relates to a method of preparing a composition according to the **first aspect**, or according to the method of the **first aspect** and any embodiment or any combination of at least two embodiments defined therein, wherein the hyaluronic acid, or the hyaluronic acid and the anesthetic and/or anti-arrhythmic, are the only active ingredients of the composition.

[00201] According to a **second aspect**, the invention relates to a composition, such as a gel, comprising a crosslinked first polymer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide such as HA.

[00202] In one embodiment, the composition, such as a gel, comprising a crosslinked first polymer, optionally a second polymer, which may be crosslinked or

non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, is obtainable by the method according to the **first aspect** of the invention, or is obtainable by the method according to the **first aspect** and any embodiment or any combination of at least two embodiments defined therein.

[00203] In one embodiment, the composition, such as a gel, consisting of a crosslinked first polymer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, and optionally an anesthetic and/or anti-arrhythmic, wherein the first and the second polymer are selected from a polysaccharide, is obtainable by the method according to the **first aspect** of the invention, or is obtainable by the method according to the **first aspect** and any embodiment or any combination of at least two embodiments described therein.

[00204] According to a **third aspect**, the invention relates to a kit, the kit comprising a syringe and the composition, such as a gel, according to the **second aspect**, or a syringe and the composition, such as a gel, prepared according to the method according to the **first aspect**.

[00205] According to a **fourth aspect**, the invention relates to the use of the composition, such as a gel, according to the **second aspect**, or to the composition, such as a gel, prepared according to the **first aspect**, in a cosmetic application.

[00206] In one embodiment, the composition, such as a gel, is used as a dermatological filler.

[00207] The term "*dermatological filler*" as used herein means that the composition such as a gel prepared according to the invention is suitable for increasing the volume of skin tissue, i.e. to augment skin tissue.

[00208] In one embodiment, the composition such as a gel is used to augment skin tissue such as to augment skin face tissue, and / or to correct moderate or deep wrinkles.

[00209] In one embodiment, the composition is an injectable composition, i.e. it is injected into skin tissue when applied.

[00210] According to a further aspect, the composition according to the **second aspect** may be used as a pharmaceutical composition or in a pharmaceutical composition

[00211] In one embodiment, the composition is used in medical applications, which require the use of compositions, such as gels, based on hyaluronic acid.

[00212] Thus, according to a **fifth aspect**, the invention relates to a composition, such as a gel, according to the **second aspect** for use as a medicament.

[00213] According to a **sixth aspect**, the invention relates to a method of preparing a composition, such as a gel, the composition comprising a crosslinked first polymer, and optionally a second polymer, the second polymer may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, the method comprising at least a first sieving step (a).

[00214] The term "*sieving step*" encompasses a step in which a crosslinked polymer, such as a crosslinked hyaluronic acid, and water, are extruded through a sieve.

[00215] In one embodiment, the term "*sieving step*" encompasses a step in which a product obtained in any one of steps (i) to (vi) as defined with respect to the **first**

aspect of the invention is extruded through a sieve. The term "*extruded through a sieve*" as e.g. mentioned under the **first aspect** of the invention encompasses terms such as "*passed through a sieve*", or "*pressed through a sieve*" or "*directed through a sieve*" or "*filtered*".

[00216] The term "*sieve*" encompasses the term "*filter*".

[00217] The term "*sieve*" or "*filter*" encompasses any device having pores or holes through which a liquid may penetrate, wherein particles, which may be contained in the liquid, may be removed or which may be sheared to fit through the pores of the sieve or the filter. Thus, in one embodiment, the particles are resized by sieving or filtering. The sieve may e.g. be provided in the form of a net of metal wires or fibers such as plastic fibers. Suitable sieves are known in the field of sieving and filtering.

[00218] In one embodiment, the method comprises at least a second sieving step (b).

[00219] In another embodiment, the method comprises besides the first sieving step (a) and the second sieving step (b) at least a third sieving step (c).

[00220] In another embodiment, the method comprises besides the first sieving step (a) and the second sieving step (b) and the third sieving step (c) at least one further sieving step, or at least two further sieving steps, or at least three further sieving steps, or at least four further sieving steps.

[00221] In one embodiment, the second sieving step (b) is performed using a second sieve having a mesh size that is less than the mesh size of a first sieve that is used in the first sieving step (a).

[00222] In another embodiment, the third sieving step (c) is performed using a third sieve having a mesh size that is less than the mesh size of the second sieve used in the second sieving step (b).

[00223] In another embodiment, the third sieving step (c) is performed using a third sieve having a mesh size that is less than the mesh size of the second sieve used in the second sieving step (b), which in turn has a mesh size that is less than the mesh size of the first sieve used in the first sieving step (a).

[00224] In still another embodiment, each subsequently used sieve has a mesh size that is less than the mesh size of a sieve used in the preceding sieving step.

[00225] In one embodiment, the first sieve has a mesh size in the range of from 200 to 600 μm .

[00226] In another embodiment, the first sieve has a mesh size in the range of from 200 to 600 μm ; and the second sieve has a mesh size in the range of from 100 to 400 μm .

[00227] In still another embodiment, the first sieve has a mesh size in the range of from 200 to 600 μm ; and the second sieve has a mesh size in the range of from 100 to 400 μm ; and the third sieve has a mesh size in the range of from 50 to 300 μm .

[00228] In one embodiment, the first sieve has a mesh size in the range of from 300 to 500 μm .

[00229] In another embodiment, the first sieve has a mesh size in the range of from 300 to 500 μm ; and the second sieve has a mesh size in the range of from 100 to 300 μm .

[00230] In still another embodiment, the first sieve has a mesh size in the range of from 300 to 500 μm ; and the second sieve has a mesh size in the range of from 100 to 300 μm ; and the third sieve has a mesh size in the range of from 50 to 200 μm .

[00231] In one embodiment, the first sieve has a mesh size in the range of from 325 to 425 μm .

[00232] In another embodiment, the first sieve has a mesh size in the range of from 325 to 425 μm ; and the second sieve has a mesh size in the range of from 175 to 225 μm .

[00233] In another embodiment, the first sieve has a mesh size in the range of from 325 to 425 μm ; and the second sieve has a mesh size in the range of from 175 to 225 μm ; and the third sieve has a mesh size in the range of from 110 to 170 μm .

[00234] In one embodiment, the sieving according to at least one of the sieving steps (a), (b) or (c) is performed at a temperature of from 5 to 30 °C such as 5 to 25 °C or 5 to 20 °C or 5 to 15 °C or 5 to 10 °C.

[00235] In one embodiment, prior or subsequent to the first sieving step (a), or prior or subsequent to the second sieving step (b), or prior or subsequent to the third sieving step (c), the method comprises at least one of the following steps (i) to (vi) as defined with respect to the **first aspect** of the invention.

[00236] Accordingly, in one embodiment of the **sixth aspect**, prior or subsequent to the first sieving step (a), or prior or subsequent to the second sieving step (b), or prior or subsequent to the third sieving step (c), the method comprises at least one of the following steps (i) to (vi):

- (i) crosslinking a mixture comprising the first polymer and water;
- (ii) subsequent to the crosslinking in step (i), terminating the crosslinking;
- (iii) optionally blending the product obtained in step (ii) with the second polymer;
- (iv) subjecting the product obtained in step (ii), or step (iii) to dialysis;
- (v) admixing an anesthetic and/or anti-arrhythmic such as lidocaine, or lidocaine hydrochloride, or lidocaine hydrochloride monohydrate, or tetracaine, or lidocaine and tetracaine, to the product obtained in step (iv);
- (vi) filling the product obtained in step (v) into a syringe and sterilizing it.

[00237] In another embodiment, prior or subsequent to the first sieving step (a), or prior or subsequent to the second sieving step (b), or prior or subsequent to the third sieving step (c), the method comprises at least one of the following steps (i) to (vi):

- (i) crosslinking a mixture comprising the first polymer and water;
- (ii) subsequent to the crosslinking in step (i), terminating the crosslinking;
- (iii) optionally blending the product obtained in step (ii) with the second polymer;
- (iv) subjecting the product obtained in step (i), or step (ii), or step (iii) to dialysis;
- (v) admixing an anesthetic and/or anti-arrhythmic such as lidocaine, or lidocaine hydrochloride, or lidocaine hydrochloride monohydrate, or tetracaine, or lidocaine and tetracaine, to the product obtained in step (i), or step (ii), or step (iii), or step (iv);
- (vi) filling the product obtained in step (i), or step (ii), or step (iii), or step (iv), or step (v) into a syringe and sterilizing it.

[00238] In one embodiment, the first sieving step (a) is performed subsequently to step (i).

[00239] In another embodiment, the first sieving step (a) and the second sieving step (b) are performed subsequently to step (i).

[00240] In still another embodiment, the first sieving step (a) and the second sieving step (b) and the third sieving step (c) are performed subsequently to step (i).

[00241] In one embodiment, the first sieving step (a) is performed subsequently to step (ii).

[00242] In another embodiment, the first sieving step (a) and the second sieving step (b) are performed subsequently to step (ii).

[00243] In still another embodiment, the first sieving step (a) and the second sieving step (b) and the third sieving step (c) are performed subsequently to step (ii).

[00244] In one embodiment, the first sieving step (a) is performed subsequently to step (iii).

[00245] In another embodiment, the first sieving step (a) and the second sieving step (b) are performed subsequently to step (iii).

[00246] In still another embodiment, the first sieving step (a) and the second sieving step (b) and the third sieving step (c) are performed subsequently to step (iii).

[00247] In one embodiment, the first sieving step (a) is performed subsequently to step (iv).

[00248] In another embodiment, the first sieving step (a) and the second sieving step (b) are performed subsequently to step (iv).

[00249] In still another embodiment, the first sieving step (a) and the second sieving step (b) and the third sieving step (c) are performed subsequently to step (iv).

[00250] In one embodiment, the first sieving step (a) is performed subsequently to step (v).

[00251] In another embodiment, the first sieving step (a) and the second sieving step (b) are performed subsequently to step (v).

[00252] In still another embodiment, the first sieving step (a) and the second sieving step (b) and the third sieving step (c) are performed subsequently to step (v).

[00253] The use of sieves supports the removal of extraneous compounds and particles such as gelled particles, which may negatively affect the desired homogeneity of the product, or helps to resize the particles to fit through the pores of the sieve by applying shear forces. Thus, in one embodiment, a sieving step or several sieving steps used in the method according to the invention allow(s) for the preparation of a particularly homogeneous composition, i.e. a particularly homogeneous gel comprising the first polymer, optionally a second polymer, and water. Homogeneity supports and improves the intended application such as the application of the composition in a cosmetic or medical use.

[00254] According to a **seventh aspect**, the invention relates to a composition, such as a gel, the composition comprising a crosslinked first polymer, and optionally a second polymer, the second polymer may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, prepared or obtainable by a method as defined in the **sixth aspect** of the invention, or in any one of the embodiments or in any one of at least two embodiments defined in the **sixth aspect**.

[00255] According to an **eighth aspect**, the invention relates to a kit, the kit comprising a syringe and the composition prepared or obtainable by a method as defined in the **sixth aspect** of the invention, or in any one of the embodiments of the **sixth aspect**, or to a kit comprising a syringe and a composition as defined in the **seventh aspect** of the invention.

[00256] According to a **ninth aspect**, the invention relates to the use of the composition prepared or obtainable by a method as defined in the **sixth aspect** of the invention, or in any one of the embodiments or in any one of at least two embodiments defined in the **sixth aspect**, or to the use of the composition as defined in the **seventh aspect** of the invention, in a cosmetic application; or as a dermatological filler.

[00257] According to a **tenth aspect**, the invention relates to a composition, such as a gel, the composition comprising a crosslinked first polymer, and optionally a second polymer, the second polymer may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, prepared or obtainable by a method as defined in the **sixth aspect** of the invention, or in any one of the embodiments or in any one of at least two embodiments defined

in the **sixth aspect**, or to a composition as defined in the **seventh aspect** of the invention, for use as a medicament.

[00258] According to an **eleventh aspect**, the invention relates to the use of at least one sieve or at least one sieving step in the preparation of a composition comprising a crosslinked hyaluronic acid and water.

[00259] In one embodiment of this use, at least two sieves or two sieving steps are used.

[00260] In another embodiment, at least three sieves are or at least three sieving steps are used.

EXAMPLES

Example 1

Preparation of buffer solution

[00261] A buffer solution is made from sodium chloride, dibasic anhydrous sodium phosphate, monobasic sodium phosphate dihydrate and water by dissolving the salts in water.

Preparation of HA in buffer

[00262] Subsequent to the preparation of the buffer solution, sodium hyaluronate having a molecular weight of from 2.5 MDa to less than 3.0 MDa is added to a quart mixing bowl and a portion of the buffer solution is added to it. The contents are mixed for 2.0 to 2.5 hours using a stirrer at 250 rpm while the jacket setpoint on the mixing bowl is set to 50 °C. Subsequent to the mixing, the contents are then cooled to 5 to 7 °C.

Addition of alkaline solution

[00263] A first alkaline solution is prepared by dissolving sodium hydroxide in the above buffer solution. Then, a second alkaline solution is prepared by dissolving sodium hydroxide in the above buffer solution. The first alkaline solution is then added to the contents in the mixing bowl and the contents are mixed for 30 to 40 minutes at 250 rpm at a 5 °C jacket set point.

Crosslinking reaction [step (i)]

[00264] The crosslinking solution is prepared by adding BDDE to a portion of the second alkaline buffer solution. This alkaline solution comprising the crosslinking agent BDDE is added to the contents in the mixing bowl and allowed to mix for 10 to 15 minutes at 500 rpm at a 5 °C jacket setpoint. The mixing speed is then lowered to 100 rpm and the temperature set point is changed to a temperature of 30 °C. After a

temperature of 28 °C has been reached, the mixing is turned off, and the contents are allowed to set for approx. 3 hours.

Preparation of a quench solution for the termination of the crosslinking reaction

[00265] A 1M HCl solution is added to a portion of the buffer solution to create a quench solution.

Quenching reaction fstep (ii)

[00266] The temperature setpoint on the jacket is set to 5 °C and the quench solution is added to the bowl contents. The contents are then mixed for 10 to 15 minutes at 500 rpm.

Processing of the crosslinked HA

[00267] The polymer resulting from step (ii) is then cut into pieces, which may be formed as chunks or strips. The size of the chunks or stripes may be 1,27 cm x 1,27 cm x 1,27 cm (0.5 x 0.5 x 0.5 inches) or smaller. The chunks or strips are then mixed for approximately 2.5 to 3.0 hours at 150 rpm at a 5 °C jacket setpoint. Subsequent to the mixing, the mixed product is extruded through a 558.8 μm [0.022 "] screen and placed back into the mixing bowl and further mixed for 2.0 to 2.5 hours at 150 rpm at a 5 °C jacket setpoint.

Provision of the second polymer

[00268] HA (sodium salt) having $M_w \geq 3.0$ MDa is added to a portion of the buffer solution. The contents are mixed with an overhead mixer for a short period of time.

Preparation of a gel [step (iii)]

[00269] A portion of the second polymer in the buffer (1 % w/w) is added to the contents in the quart mixer. The contents are allowed to mix for 1 to 5 min at 250 rpm.

Dialysis reaction [step (iv)]

[00270] Dialysis membranes having a MWCO of from 12,000 to 14,000 Da are hydrated in sterile water. Then, the gel obtained in step (iii) is extruded through a screen having a mesh size of approximately 380 μm , such as 381 μm (0.015"), then through a screen having a mesh size of approximately 200 μm , such as 203.2 μm (0.008"), then through a screen having a mesh size of approximately 140 μm , such as 139.7 μm (0.0055"), into the dialysis membranes. The dialysis membranes are filled and have an effective length of approximately 20.3 cm (8 inches) and an overall length of approximately 25.4 cm (10 inches). The membranes are then placed into a container containing the above buffer solution. The container is cooled down to 5 °C setpoint and the content is stirred. The dialysis solution is exchanged twice at an interval of 12 ± 2 hours. The dialysis is allowed to proceed for 37 ± 2 hours.

Extrusion of the product obtained in step (iv) [step (vi)]

[00271] After dialysis the membranes are combined, mixed and extruded twice through a sieve having a mesh size of approximately 140 μm , such as 139.7 μm (0.0055"), and are then further mixed for 30 to 40 min under vacuum. The resulting material is extruded into syringes and is steam sterilized.

[00272] The product obtained after step (iv) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

Example 2

[00273] The reaction is performed according to Example 1 with the difference in crosslinking step (i):

[00274] The crosslinking solution is prepared by adding BDDE to a portion of the second alkaline buffer solution. This alkaline solution comprising the crosslinking agent BDDE is added to the contents in the mixing bowl and allowed to mix for 10 to 15 minutes at 500 rpm at a 5 °C jacket setpoint. The mixing speed is then lowered to 100 rpm and the temperature set point is changed to a temperature of 33.33 °C. After a temperature of 31.33 °C has been reached, the mixing is turned off, and the contents are allowed to set for approx. 3 hours.

[00275] The product obtained after step (iv) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin. This gel has a higher elasticity and viscosity than the gel according to Example 1.

Example 3

[00276] The reaction is performed according to Example 1 with the difference that an anesthetic and anti-arrhythmic such as lidocaine is added to the gel obtained after step (iii):

Lidocaine addition [step (v)1

[00277] A solution of lidocaine HCl monohydrate is dissolved in the buffer solution and is added to the dialysis membranes containing the gel prepared according to step (iii) in an amount of 0.35 wt.-% based on gel. The contents may be extruded twice through a sieve having a mesh size of approximately 140 μm, such as 139.7 μm (0.0055 "), and are then further mixed for 30 to 40 min under vacuum.

[00278] The product obtained after step (v) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an

implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

Example 4

[00279] The reaction is performed according to Example 1 with the difference in crosslinking step (i):

[00280] The crosslinking solution is prepared by adding BDDE to a portion of the second alkaline buffer solution. This alkaline solution comprising the crosslinking agent BDDE is added to the contents in the mixing bowl and allowed to mix for 10 to 15 minutes at 500 rpm at a 5 °C jacket setpoint. The mixing speed is then lowered to 100 rpm and the temperature set point is changed to a temperature of 27 °C. After a temperature of 25 °C has been reached, the mixing is turned off, and the contents are allowed to set for approx. 3 hours.

[00281] The product obtained after step (iv) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin. This gel has a lower elasticity and viscosity than the gel according to Example 1.

Example 5

[00282] The reaction is performed according to Example 1 with the difference in crosslinking step (i) and blending step (iii):

[00283] The crosslinking solution is prepared by adding BDDE to a portion of the second alkaline buffer solution. This alkaline solution comprising the crosslinking agent BDDE is added to the contents in the mixing bowl and allowed to mix for 10 to

15 minutes at 500 rpm at a 5 °C jacket setpoint. The mixing speed is then lowered to 100 rpm and the temperature set point is changed to a temperature of 30 °C. After a temperature of 27 °C has been reached, the mixing is turned off, and the contents are allowed to set for approx. 3 hours.

Provision of the second polymer

[00284] HA (sodium salt) having $M_w \geq 3.0$ MDa is added to a portion of the buffer solution. The contents are mixed with an overhead mixer for a short period of time.

Preparation of a gel [step (iii)]

[00285] A portion of the second polymer in the buffer (3 % w/w) is added to the contents in the quart mixer. The contents are allowed to mix for 1 to 5 min at 250 rpm.

[00286] The product obtained after step (iv) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

Example 6

[00287] The reaction is performed according to Example 1 with the difference in crosslinking step (i) and blending step (iii):

[00288] The crosslinking solution is prepared by adding BDDE to a portion of the second alkaline buffer solution. This alkaline solution comprising the crosslinking agent BDDE is added to the contents in the mixing bowl and allowed to mix for 10 to 15 minutes at 500 rpm at a 5 °C jacket setpoint. The mixing speed is then lowered to 100 rpm and the temperature set point is changed to a temperature of 25 °C. After a

temperature of 22 °C has been reached, the mixing is turned off, and the contents are allowed to set for approx. 3 hours.

Provision of the second polymer

[00289] HA (sodium salt) having $M_w > 3.0$ MDa is added to a portion of the buffer solution. The contents are mixed with an overhead mixer for a short period of time. Subsequently, a portion of the crosslinking solution used in step (i) is added to the second polymer in the buffer solution.

Preparation of a gel [step (iii)]

[00290] A portion of the crosslinked second polymer in the buffer (1 % w/w) is added to the contents in the quart mixer. The contents are allowed to mix for 1 to 5 min at 250 rpm.

[00291] The product obtained after step (iv) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

Example 7

[00292] The reaction is performed according to Example 2 with the difference that an anesthetic and anti-arrhythmic such as lidocaine is added to the gel obtained after step (iii):

Lidocaine addition [step (v)1]

[00293] A solution of lidocaine HCl monohydrate is dissolved in the buffer solution and is added to the dialysis membranes containing the gel prepared according to step (iii) in an amount of 0.35 wt.-% based on gel. The contents may be extruded twice through a sieve having a mesh size of approximately 140 μm , such as 139.7 μm (0.0055"), and are then further mixed for 30 to 40 min under vacuum.

[00294] The product obtained after step (v) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

Example 8

[00295] The reaction is performed according to Example 1 with the difference that after step (ii) blending step (iii) is omitted.

[00296] The product obtained after step (iv) and contained in the syringe after step (vi) is an isotonic, sterile, viscoelastic injectable gel. This gel may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

Examples 9 to 14

[00297] The reaction is performed according to Examples 2 to 7 with the difference that after step (ii) blending step (iii) is omitted.

[00298] The products that are respectively obtained after step (iv) and that are contained in the syringe after step (vi) are isotonic, sterile, viscoelastic injectable gels. Said gels may be used as an implant suitable to increase the volume of e.g. face skin tissue, i.e. to augment said skin tissue, and / or to correct moderate or deep wrinkles of the skin.

CLAIMS

1. Method of preparing a composition, such as a gel, the composition comprising a crosslinked first polymer, optionally a second polymer, the second polymer may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, comprising at least steps (i) to (iv):
 - (i) crosslinking a mixture comprising the first polymer and water;
 - (ii) subsequent to the crosslinking in step (i), terminating the crosslinking;
 - (iii) optionally blending the product obtained in step (ii) with the second polymer;
 - (iv) subjecting the product obtained in step (ii) or step (iii) to dialysis.
2. Method of Claim 1, wherein the first and the second polymer may be the same or may be different from one another.
3. Method of Claim 1 or 2, wherein the second polymer is non-crosslinked.
4. Method of any one of the preceding Claims, wherein the first and the second polymer are selected from a hyaluronic acid and/or a sodium salt thereof.
5. Method of any one of the preceding Claims, wherein the first polymer used in step (i) has a molecular weight Mw of from 2.5 MDa to less than 3.0 MDa.

6. Method of any one of the preceding Claims, wherein the second polymer used in step (iii) has a molecular weight of at least 3.0 MDa.
7. Method of any one of the preceding Claims, wherein the weight of the second polymer based on the weight of the first polymer is less than 5 %, or less than 4 %, e.g. is in the range of from 0.01 to 5 %, or is in the range of from 0.1 to 4 %, or is in the range of from 0.1 to 2.5 %, or from 0.2 to 2.0 %, or from 0.5 to 1.5 %.
8. Method of any one of the preceding Claims, further comprising step (v):
 - (v) admixing an anesthetic and/or anti-arrhythmic such as lidocaine, or lidocaine hydrochloride, or lidocaine hydrochloride monohydrate, or tetracaine, or lidocaine and tetracaine, to the product obtained in step (iv).
9. Method of any one of the preceding Claims, further comprising step (vi):
 - (vi) filling the product obtained in step (iv) or step (v) into a syringe and sterilizing it.
10. Method of any one of the preceding claims, wherein step (ii) comprises step (ii.1), or steps (ii.1) and (ii.2):
 - (11.1) subjecting the product obtained in step (i) to an acid;
 - (11.2) extruding the product obtained in step (ii.1); or
extruding the product obtained in step (ii.1) through a sieve; or

extruding the product obtained in step (ii.1) through a sieve having a mesh size in the range of from 500 to 600 pm, e.g. 558.8 μm .

11. Method of any one of the preceding Claims, wherein said dialysis step (iv) comprises steps (iv.1) to (iv.3):

(iv.1) extruding the product obtained in step (iii) through a first sieve and subsequently extruding the extruded product from the first sieve through a second sieve, wherein the mesh size of the second sieve is less than the mesh size of the first sieve; or

extruding the product obtained in step (iii) through a first sieve, and subsequently extruding the extruded product from the first sieve through a second sieve, and subsequently extruding the extruded product from the second sieve through a third sieve, wherein the mesh size of the second sieve is less than the mesh size of the first sieve, and the mesh size of the third sieve is less than the mesh size of the second sieve; or extruding the product obtained in step (iii) through a first sieve having a mesh size in the range of from 325 to 425 pm; and subsequently extruding the extruded product from the first sieve through a second sieve having a mesh size in the range of from 175 to 225 pm; and subsequently extruding the extruded product from the second sieve through a third sieve having a mesh size in the range of from 110 to 170 pm;

(iv.2) filling the product obtained in step (iv.1) into a dialysis membrane; or filling the product obtained in step (iv.1) into a dialysis membrane having a molecular weight cut off in the range of from 12,000 to 14,000 Da;

- (iv.3) subjecting the filled membrane obtained in step (iv.2) to a dialysis solution.
12. Composition, such as a gel, the composition comprising a crosslinked first polymer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, obtainable by a method according to any one of Claims 1 to 11.
 13. Kit, the kit comprising a syringe and the composition prepared according to the method as defined in any one of Claims 1 to 11; or comprising a syringe and the composition of Claim 12.
 14. Use of the composition prepared according to the method as defined in any one of Claims 1 to 11, or use of the composition according to Claim 12, in a cosmetic application; or use of the composition prepared according to the method as defined in any one of Claims 1 to 11, or use of the composition according to Claim 12, as a dermatological filler.
 15. Composition, such as a gel, the composition comprising a crosslinked first polymer, optionally a second polymer, which may be crosslinked or non-crosslinked, and water, wherein the first and the second polymer are selected from a polysaccharide, obtainable by a method according to any one of Claims 1 to 11, for use as a medicament.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2013/001782

A. CLASSIFICATION OF SUBJECT MATTER
 INV. C08B37/08 C08L5/08 A61K8/73 A61K31/728 A61K47/36
 A61L27/52 C08J3/075 A61K9/00 C08J3/24
 ADD.
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 C08B C08L A61K A61L C08J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 EPO-Internal , WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 466 300 A2 (BIOMATRIX INC [US]) 15 January 1992 (1992-01-15) cited in the application examples 2, 12, 21 -----	1-15
A	US 4 713 448 A (BALAZS ENDRE A [US] ET AL) 15 December 1987 (1987-12-15) example 11 -----	1-15
X	US 8 052 990 B2 (HERMITTE LAURENCE [FR] ET AL) 8 November 2011 (2011-11-08) examples 1, 4 & EP 1 711 552 B1 (ANTEIS S A [CH]) 24 November 2010 (2010-11-24) cited in the application ----- -/- .	1-15

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 11 September 2013	Date of mailing of the international search report 24/09/2013
--	--

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Lanz , Sandra
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2013/001782

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	wo 2010/015900 AI (ALLERGAN IND SAS [FR] ; LEBRETON PIERRE [FR]) 11 February 2010 (2010-02-11) cited in the application example 2	1-15
X	----- wo 2009/098127 AI (KEYSAN CONSULTING [FR] ; HERMITTE LAURENCE [FR]) 13 August 2009 (2009-08-13) cited in the application examples 2,3	1-15
X	----- wo 2012/062775 AI (ALLERGAN IND SAS [FR] ; LEBRETON PIERRE [FR]) 18 May 2012 (2012-05-18) example 1	1-15
X	----- wo 2010/115081 A2 (ALLERGAN INC [US] ; STROUMP0ULIS DIMITRIOS [US] ; HEREDIA GUI LLEN KARINA) 7 October 2010 (2010-10-07) examples 3,4	1-15
X	----- US 2010/316683 AI (PI RON ESTELLE [FR] ET AL) 16 December 2010 (2010-12-16) paragraph [0064] & wo 2008/068297 AI (FABRE PIERRE DERMO COSMETIQUE [FR] ; PI RON ESTELLE [FR]) 12 June 2008 (2008-06-12) cited in the application	1-15
X	----- wo 2011/119468 AI (ALLERGAN INC [US] ; GUI LLEN KARINA HEREDIA [US] ; TEZEL AHMET [US]) 29 September 2011 (2011-09-29) cited in the application examples 1,6	1-15
X	----- wo 93/15117 AI (COULTER CORP [US]) 5 August 1993 (1993-08-05) page 21, lines 2-7 ; example 6	1-3 ,5-15
X	----- US 4 920 194 A (FELLER WOLFGANG [DE] ET AL) 24 April 1990 (1990-04-24) column 13, lines 31-48	1-3 ,5-15
X	----- US 2011/166530 AI (KREINER CHRISTINE [DE] ET AL) 7 July 2011 (2011-07-07) claim 1 & wo 2009/021526 AI (S & V TECHNOLOGIES AG [DE] ; KREINER CHRISTINE [DE] ; NACHBAUR LIDIA [DE]) 19 February 2009 (2009-02-19) cited in the application	1-15
6 1	X wo 97/04012 AI (AAGERUP BENGT [SE]) 6 February 1997 (1997-02-06) example 3 -/--	1-15

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2013/001782

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>& EP 0 839 159 BI (Q MED AB [SE]) 8 August 2001 (2001-08-08) cited in the applicati on ----- wo 2009/073437 AI (ALLERGAN INC [US] ; STROUMPOULIS DIMITRIOS [US] ; MUDD CHRISTOPHER S [US] 11 June 2009 (2009-06-11) exampl e 5 -----</p>	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/001782

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0466300	A2	15-01-1992	AT 165979 T 15-05-1998
			AU 629467 B2 01-10-1992
			CA 2041074 AI 10-01-1992
			DE 69129391 DI 18-06-1998
			DE 69129391 T2 08-10-1998
			DK 0466300 T3 07-10-1998
			EP 0466300 A2 15-01-1992
			ES 2117634 T3 16-08-1998
			HK 1011502 AI 09-07-1999
			JP H0793943 B2 11-10-1995
			JP H04261664 A 17-09-1992
			US 5143724 A 01-09-1992
US 4713448	A	15-12-1987	AU 560956 B2 30-04-1987
			AU 583464 B2 27-04-1989
			AU 5289186 A 18-09-1986
			AU 7618087 A 29-10-1987
			BE 904357 AI 30-06-1986
			CA 1276143 C 13-11-1990
			CH 670092 A5 12-05-1989
			DE 3607897 AI 18-09-1986
			DE 3645191 C2 10-12-1992
			DE 3645226 C2 15-07-1993
			FR 2582002 AI 21-11-1986
			GB 2172295 A 17-09-1986
			IT 1191981 B 31-03-1988
			JP H0353321 B2 14-08-1991
			JP H01198602 A 10-08-1989
			JP S61207401 A 13-09-1986
			NL 8600644 A 01-10-1986
			SE 468830 B 29-03-1993
			SE 8601135 A 13-09-1986
	US 4713448 A 15-12-1987		
US 8052990	B2	08-11-2011	AT 489420 T 15-12-2010
			AU 2005219595 AI 15-09-2005
			BR PI0507294 A 03-07-2007
			CA 2554597 AI 15-09-2005
			CN 1918219 A 21-02-2007
			EP 1711552 AI 18-10-2006
			ES 2354699 T3 17-03-2011
			FR 2865737 AI 05-08-2005
			JP 5105274 B2 26-12-2012
			JP 2007520612 A 26-07-2007
			KR 20070004611 A 09-01-2007
			RU 2377260 C2 27-12-2009
			US 2007196426 AI 23-08-2007
			Wo 2005085329 AI 15-09-2005
Wo 2010015900	AI	11-02-2010	AU 2009278883 AI 11-02-2010
			AU 2009278884 AI 11-02-2010
			CA 2732788 AI 11-02-2010
			CA 2732928 AI 11-02-2010
			CN 102170855 A 31-08-2011
			CN 102170856 A 31-08-2011
			EP 2323617 AI 25-05-2011
			EP 2326302 AI 01-06-2011
			JP 2011529762 A 15-12-2011

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/001782

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 2011529763 A	15-12 -2011
		KR 20110040966 A	20-04 -2011
		KR 20110043730 A	27-04 -2011
		US 2010028437 AI	04-02 -2010
		US 2010028438 AI	04-02 -2010
		US 2012172328 AI	05-07 -2012
		US 2013041038 AI	14-02 -2013
		US 2013041039 AI	14-02 -2013
		US 2013131011 AI	23-05 -2013
		W0 2010015900 AI	11-02 -2010
		W0 2010015901 AI	11-02 -2010

W0 2009098127	AI	13-08-2009	
		EP 2254584 AI	01-12-2010
		FR 2927255 AI	14-08-2009
		W0 2009098127 AI	13-08-2009

W0 2012062775	AI	18-05-2012	
		AU 2011328219 AI	13-06-2013
		CA 2816927 AI	18-05-2012
		EP 2637710 AI	18-09-2013
		W0 2012062775 AI	18-05-2012

W0 2010115081	A2	07-10-2010	
		AU 2010232547 AI	27-10 -2011
		CA 2757557 AI	07-10 -2010
		EP 2413894 A2	08-02 -2012
		US 2010255068 AI	07-10 -2010
		US 2012034462 AI	09-02 -2012
		W0 2010115081 A2	07-10 -2010

US 2010316683	AI	16-12-2010	
		AR 064175 AI	18-03 -2009
		AU 2007328917 AI	12-06 -2008
		CA 2671793 AI	12-06 -2008
		CN 101594892 A	02-12 -2009
		EP 2152329 AI	17-02 -2010
		EP 2489374 AI	22-08 -2012
		FR 2909560 AI	13-06 -2008
		IL 199002 A	31-01 -2013
		JP 2010511454 A	15-04 -2010
		KR 20090085102 A	06-08 -2009
		MA 30978 BI	01-12 -2009
		NZ 577917 A	12-01 -2012
		RU 2009125201 A	20-01 -2011
		TW 200836778 A	16-09 -2008
		US 2010316683 AI	16-12 -2010
		W0 2008068297 AI	12-06 -2008
		ZA 200903919 A	30-06 -2010

W0 2011119468	AI	29-09-2011	
		AU 2011229730 AI	01-11-2012
		CA 2794254 AI	29-09-2011
		EP 2550027 AI	30-01-2013
		US 2011229574 AI	22-09-2011
		W0 2011119468 AI	29-09-2011

W0 9315117	AI	05-08-1993	
		AU 3608993 A	01-09- 1993
		CA 2128230 AI	05-08- 1993
		CN 1074844 A	04-08- 1993
		EP 0625993 AI	30-11- 1994
		IL 104455 A	18-06- 1996
		JP H07504843 A	01-06- 1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2013/001782

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		NZ 245701 A	28-03-1995
		US 5248772 A	28-09-1993
		US 5552086 A	03-09-1996
		Wo 9315117 AI	05-08-1993
		ZA 9300525 A	25-07-1994
US 4920194	A 24-04 -1990	DE 3636590 AI	26-05-1988
		EP 0265865 A2	04-05-1988
		ES 2032799 T3	01-03-1993
		JP S63122629 A	26-05-1988
		US 4920194 A	24-04-1990
US 2011166530	AI 07-07 -2011	CA 2658681 AI	19-02-2009
		EP 2170961 AI	07-04-2010
		US 2011166530 AI	07-07-2011
		Wo 2009021526 AI	19-02-2009
wo 9704012	AI 06-02-1997	AT 204000 T	15-08 -2001
		AU 700215 B2	24-12 -1998
		BR 9609534 A	23-02 -1999
		CA 2226488 AI	06-02 -1997
		CN 1190974 A	19-08 -1998
		CZ 9800129 A3	17-06 -1998
		DE 839159 T1	07-10 -1999
		DE 69614391 D1	13-09 -2001
		DE 69614391 T2	14-02 -2002
		DK 0839159 T3	08-10 -2001
		EA 980133 AI	29-10 -1998
		EP 0839159 AI	06-05 -1998
		ES 2161368 T3	01-12 -2001
		GR 3037065 T3	31-01 -2002
		HU 9901714 A2	28-09 -1999
		JP 3094074 B2	03-10 -2000
		JP H11509256 A	17-08 -1999
		NO 980213 A	16-03 -1998
		NZ 312229 A	25-11 -1998
		PL 324608 AI	08-06 -1998
		PT 839159 E	30-11 -2001
		SI 0839159 T1	30-04 -2002
		SK 6198 A3	11-01 -1999
		TR 9800072 T1	21-05 -1998
		US 5827937 A	27-10 -1998
		wo 9704012 AI	06-02 -1997
wo 2009073437	AI 11-06-2009	AU 2008331602 AI	11-06 -2009
		CA 2706880 AI	11-06 -2009
		CN 101951879 A	19-01 -2011
		EP 2219595 AI	25-08 -2010
		JP 2011505362 A	24-02 -2011
		KR 20100117563 A	03-11 -2010
		NZ 585814 A	21-12 -2012
		RU 2010125704 A	10-01 -2012
		US 2009143331 AI	04-06 -2009
		US 2010004198 AI	07-01 -2010
		US 2013209532 AI	15-08 -2013
		wo 2009073437 AI	11-06 -2009